{"id":"dupilumab-sar231893-regn668","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Injection site reactions"},{"rate":"10–15","effect":"Conjunctivitis"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Oropharyngeal pain"},{"rate":"5–10","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL2108675","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing IL-4 receptor alpha, dupilumab suppresses the IL-4/IL-13 signaling pathway, which drives type 2 immune responses and inflammation. This mechanism reduces eosinophil recruitment, IgE production, and other hallmarks of type 2 inflammatory diseases including atopic dermatitis, asthma, and eosinophilic conditions. The drug effectively dampens the underlying Th2-mediated immune dysregulation common to these conditions.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:05.829Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Moderate-to-severe asthma (particularly type 2/eosinophilic)"},{"name":"Chronic rhinosinusitis with nasal polyps"},{"name":"Eosinophilic esophagitis"}]},"trialDetails":[{"nctId":"NCT06693531","phase":"","title":"A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-11-22","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":350},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07112378","phase":"PHASE3","title":"A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-11-10","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":20},{"nctId":"NCT04287621","phase":"","title":"Registry of Asthma Patients Initiating DUPIXENT®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-03-02","conditions":"Asthma","enrollment":718},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT07187089","phase":"PHASE4","title":"Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-11-11","conditions":"Severe Atopic Dermatitis (AD)","enrollment":""},{"nctId":"NCT03560466","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-21","conditions":"Asthma","enrollment":378},{"nctId":"NCT04394351","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-01","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":102},{"nctId":"NCT05831176","phase":"PHASE2","title":"A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-03","conditions":"Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID)","enrollment":22},{"nctId":"NCT04776694","phase":"","title":"Compassionate Use of Dupilumab","status":"APPROVED_FOR_MARKETING","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Type 2 Inflammatory Disorders","enrollment":""},{"nctId":"NCT05976386","phase":"PHASE1","title":"Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-08","conditions":"Healthy Volunteers","enrollment":182},{"nctId":"NCT04447417","phase":"PHASE4","title":"Dupilumab Skin Barrier Function Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-16","conditions":"Atopic Dermatitis","enrollment":52},{"nctId":"NCT04823130","phase":"PHASE4","title":"Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-04-22","conditions":"Dermatitis Atopic","enrollment":54},{"nctId":"NCT04718870","phase":"PHASE4","title":"Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-02-19","conditions":"Dermatitis Atopic","enrollment":41},{"nctId":"NCT05049122","phase":"PHASE4","title":"Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-10-22","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":25},{"nctId":"NCT06087627","phase":"","title":"A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-27","conditions":"Prurigo Nodularis","enrollment":150},{"nctId":"NCT04959448","phase":"","title":"Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-08-12","conditions":"Chronic Rhinosinusitis With Nasal Polyposis","enrollment":717},{"nctId":"NCT03992417","phase":"","title":"Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2019-06-11","conditions":"Dermatitis Atopic","enrollment":955},{"nctId":"NCT05906706","phase":"","title":"Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid","status":"APPROVED_FOR_MARKETING","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Bullous Pemphigoid","enrollment":""},{"nctId":"NCT02612454","phase":"PHASE3","title":"Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-10-15","conditions":"Atopic Dermatitis","enrollment":880},{"nctId":"NCT04442269","phase":"PHASE2","title":"Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":62},{"nctId":"NCT06631677","phase":"","title":"Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)","status":"NO_LONGER_AVAILABLE","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"Food Allergy","enrollment":""},{"nctId":"NCT06192563","phase":"","title":"A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-11-30","conditions":"Dermatitis Atopic","enrollment":150},{"nctId":"NCT04417894","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-14","conditions":"Moderate to Severe Atopic Hand and Foot Dermatitis","enrollment":133},{"nctId":"NCT01949311","phase":"PHASE3","title":"Open-label Study of Dupilumab in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-10-10","conditions":"Atopic Dermatitis","enrollment":2733},{"nctId":"NCT05976360","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-11-02","conditions":"Healthy Volunteer","enrollment":38},{"nctId":"NCT05976373","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-05","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT03633617","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-09-24","conditions":"Eosinophilic Esophagitis","enrollment":321},{"nctId":"NCT04287608","phase":"","title":"Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-03-10","conditions":"Conjunctivitis, Atopic Dermatitis","enrollment":50},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT03346434","phase":"PHASE2, PHASE3","title":"Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-30","conditions":"Dermatitis, Atopic","enrollment":202},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT03793608","phase":"PHASE2","title":"Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-03-12","conditions":"Peanut Allergy","enrollment":25},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT02134028","phase":"PHASE3","title":"Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-08-05","conditions":"Asthma","enrollment":2282},{"nctId":"NCT02407756","phase":"PHASE2","title":"A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-31","conditions":"Atopic Dermatitis","enrollment":78},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT03345914","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-17","conditions":"Dermatitis, Atopic","enrollment":367},{"nctId":"NCT02277769","phase":"PHASE3","title":"Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-11-30","conditions":"Dermatitis, Atopic","enrollment":708},{"nctId":"NCT03558997","phase":"PHASE2","title":"Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-06-07","conditions":"Allergic Rhinitis","enrollment":103},{"nctId":"NCT02210780","phase":"PHASE2","title":"Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-08-05","conditions":"Atopic Dermatitis","enrollment":194},{"nctId":"NCT01979016","phase":"PHASE2","title":"Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-12-31","conditions":"Atopic Dermatitis (AD)","enrollment":54},{"nctId":"NCT02395133","phase":"PHASE3","title":"A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-25","conditions":"Atopic Dermatitis","enrollment":422},{"nctId":"NCT02379052","phase":"PHASE2","title":"Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-05-12","conditions":"Eosinophilic Esophagitis","enrollment":47},{"nctId":"NCT01385657","phase":"PHASE1","title":"Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-07-31","conditions":"Atopic Dermatitis","enrollment":37},{"nctId":"NCT02898454","phase":"PHASE3","title":"Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-28","conditions":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","enrollment":448},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT02912468","phase":"PHASE3","title":"A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-05","conditions":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","enrollment":276},{"nctId":"NCT02414854","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04-27","conditions":"Asthma","enrollment":1902},{"nctId":"NCT01548404","phase":"PHASE2","title":"Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-04","conditions":"Atopic Dermatitis","enrollment":109},{"nctId":"NCT02277743","phase":"PHASE3","title":"Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-10","conditions":"Dermatitis, Atopic","enrollment":671},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01639040","phase":"PHASE2","title":"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":31},{"nctId":"NCT01859988","phase":"PHASE2","title":"Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-05","conditions":"Atopic Dermatitis","enrollment":380},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01920893","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-08","conditions":"Nasal Polyps","enrollment":60},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT02647086","phase":"PHASE1","title":"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-12","conditions":"Atopic Dermatitis","enrollment":14},{"nctId":"NCT01537653","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-03","conditions":"Healthy","enrollment":32},{"nctId":"NCT01537640","phase":"PHASE1","title":"Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT01015027","phase":"PHASE1","title":"Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-10","conditions":"Healthy","enrollment":48},{"nctId":"NCT01259323","phase":"PHASE1","title":"Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2010-12","conditions":"Dermatitis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dupilumab (SAR231893/REGN668)","genericName":"Dupilumab (SAR231893/REGN668)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma (particularly type 2/eosinophilic), Chronic rhinosinusitis with nasal polyps.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}